Critical Therapeutics Announces Abstracts Presented at European Molecular Biology Organization HMGB1 Workshop
Friday February 17, 9:09 am ET
LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 17, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced that five abstracts related to its anti-HMGB1 (High Mobility Group Box 1) program were presented at the European Molecular Biology Organization (EMBO) Workshop, "Innate Danger Signals and HMGB1," that was held in Milan, Italy. The anti-HMGB1 program is a collaboration between Critical Therapeutics and MedImmune, Inc.
"EMBO is one of Europe's most distinguished bioscience organizations, so the acceptance of these abstracts represents major recognition from an important group of peers," said Walter Newman, Ph.D., Critical Therapeutics' chief scientific officer. "EMBO's decision to devote a specific workshop to HMGB1 highlights the significance of this cytokine and the emerging discoveries about its role in diseases."
The following posters from the Critical Therapeutics/MedImmune collaboration were presented during the workshop:
"Activities of Human Monoclonal Anti-HMGB1 Antibody in Murine Models of Sepsis," Jane Tian, et al; MedImmune, Inc., Gaithersburg, Md.
"Enrichment of Native Secreted HMGB1 From Primary Human Monocytes and Monotocyte Cell Lines," P Rao, et al; Critical Therapeutics, Inc., Lexington, Mass. and MedImmune, Inc.
"Mammalian HMGB1 Synergizes with TLR Ligands to Induce Cytokines Secretion," Su Yao Mao, Ph.D., et al; MedImmune, Inc.
"Synergy Between HMGB1 and Toll-like Receptor Ligands," S. Qin, et al; Critical Therapeutics, Inc.
"Antagonizing HMGB1 Blocks Inflammation and Tissue Damage in Experimental Arthritis," Jane Tian, et al; MedImmune, Inc.
In addition to these posters, during the EMBO workshop Gregory J. LaRosa, Ph.D., Critical Therapeutics' vice president, discovery research, delivered a presentation entitled, "Insights into the Pro-Inflammatory Activity of HMGB1, and its Blockade as a Therapy for Severe Acute Inflammation." The keynote address, "Biology of HMGB1 in Health and Disease," was delivered by Critical Therapeutics' co-founder, Kevin Tracey, M.D.... |
